港股異動丨再鼎醫藥-SB(9688.HK)低開逾4% 一季度淨虧損擴大至2.3億美元
格隆匯5月11日丨再鼎醫藥-SB(09688.HK)低開逾4%,報1170港元,總市值1030億港元。再鼎醫藥昨晚宣佈,截至2021年3月31日止3個月,公司產品淨收入為2,010萬美元,2020年同期收入為820萬美元。其中包括則樂銷售收入1,260萬美元(2020年同期為630萬美元)和愛普盾銷售收入710萬美元(2020年同期為190萬美元)。期間再鼎醫藥虧損淨額為2.329億美元,2020年同期的虧損淨額為4,800萬美元。虧損淨額的增加主要由於與argenx和Turning point的戰略合作相關付款,均記為研發費用。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.